



New member of UCB's Board of Directors

Brussels (BELGIUM), March 28, 2008 at 7:00 AM CET – UCB announces today Norman J. Ornstein as candidate to be appointed as new member of UCB's Board of Directors at next General Assembly. Norman Ornstein is resident Scholar at the American Enterprise Institute, Washington, D.C., and an expert in US congress matters. He is Ph. D. Political Science, University of Michigan and Honorary Doctor of Laws, University of Minnesota.

By the next General Assembly on April 24, 2008, mandates of four Directors will come to an end. With a view to further broadening the skills of the Board, four candidates as independent Board members have already been selected, including those announced in December 2007:

- Thomas Leysen, CEO of Umicore and next Chairman of the FEB (Federation of Belgian Companies), who will join the Board of UCB as of January 1, 2009;
- Jean-Pierre Kinet, Professor at Harvard Institute of Medicine and at the Beth Israel Deaconess Medical Center in the US;
- Armand De Decker, President of the Belgian Senate;
- And Norman Ornstein.

Further information

Antje Witte, Vice-President Corporate Communications & Investor Relations, UCB Group
T +32.2.559.9414, Antje.witte@ucb-group.com

About UCB

UCB (Brussels, Belgium) (www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing around 12 000 people in over 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB S.A. is listed on Euronext Brussels.

UCB Forward-Looking Statement

This news release contains forward-looking statements that involve risks and uncertainties, including statements with respect to the development and commercialization of certolizumab pegol. Among the factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: the results of research, development and clinical trials; the timing and success of submission, acceptance, and approval of regulatory filings; the time and resources UCB devotes to the development and commercialization of certolizumab pegol and the scope of UCB's patents and the patents of others.